- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03628521
First-line Combination Treatment Based on Anlotinib
August 9, 2018 updated by: Baohui Han, Shanghai Chest Hospital
Anlotinib-based Combination as First-line Treatment in Advanced Non-small Cell Lung Cancer: a Single Center, Three Arms and Exploratory Study
The aim of this study is to explore safety and therapeutic efficacy of anlotinib combined with erlotinib/chemotherapy/IBI308 as first-line treatment in advanced NSCLC patients.
The primary endpoints of the study are safety and objective response rate (ORR);the secondary endpoints are disease control rate (DCR), progression-free survival (PFS) and overall survival (OS).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
80
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200030
- Recruiting
- Shanghai Chest Hospital
-
Contact:
- Baohui Han, MD,PhD
- Phone Number: +8618930858216
- Email: 18930858216@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients have voluntarily to join the study and give written informed consent for the study
- Histologically documented, unresectable, inoperable, locally advanced, recurrent or metastatic stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
- A cytologic diagnosis is acceptable (i.e., FNA or pleural fluid cytology)
- Mutation status including EGFR, ALK ROS are explicit;
- At least 1 unidimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumours (RECIST) criteria.
- Patients did not receive systemic anti-cancer therapy previously, including traditional Chinese medicine.
- Able to comply with study and follow-up procedures
- Age ≥ 18 years and ≤ 75, ECOG PS: 0~1, estimated survival duration more than 3 months;enough organ function;
8)Major organ function
For regular test results(no blood transfusion within 14 days):
- Hemoglobin(HB)≥90g/L;
- Absolute neutrophils count(ANC)≥1.5×109/L;
- Blood platelets(PLT)≥80×109/L
Biochemical tests results defined as follows:
- Total bilirubin(TBIL)≤1.5 times the upper limit of normal (ULN) ;
- Alanine aminotransferase(ALT)and aspartate aminotransgerase AST≤2.5ULN,liver metastases,if any,ALT和AST≤5ULN;
- Creatinine(Cr)≤1.5ULN or Creatinine Clearance rate (CCr)≥60 ml/min;
- Doppler ultrasound assessment:left ventricular ejection fraction (LVEF) ≥the lower limit of normal value(50%).
Exclusion Criteria:
- Small cell lung cancer(including patients with mixed small cell lung cancer and non-small cell lung cancer) or central squamous cell carcinoma with cavity
- Mutation status are unknown
- Previously (within 5 years) or presently suffering from other malignancies,
- Symptomatic or uncontrolled brain metastases
- Unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months or serious cardiac arrhythmia requiring medication
- History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the patient at high risk from treatment complications
- Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, or prior surgical procedures affecting absorption
- Pregnancy or lactation
- Previously treated including treated with traditional Chinese medicine
- Patients who are allergic to any of the agent or any ingredient -
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: arm A
Anlotinib combined with erlotinib.
Anlotinib will be given at a dose of 10mg once daily on days 1-14 of a 21-day cycle.
Erlotinib will be given at a dose of 150mg once daily.
|
Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice
|
Other: arm B
Anlotinib combined with chemotherapy.
Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
Pemetrexed (just for adenocarcinoma) will be given intravenously at a dose of 500mg per square meter of body surface area every 3 weeks; gemcitabine (just for squamous carcinoma) will be given intravenously at a dose of 1000mg per square meter of body surface area every 3 weeks; carboplatin will be given intravenously with a target area under the curve of 5 mg per milliliter per minute every 3 weeks.
|
Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice
|
Other: arm C
Anlotinib combined with IBI308.
Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
IBI308 will be given intravenously at a dose of 200mg every 3 weeks.
|
Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety will be assessed according to common terminology criteria for adverse events version 4.0 (CTC AE 4.0)
Time Frame: from initiation of treatment to 90 days after the treatment finished
|
from initiation of treatment to 90 days after the treatment finished
|
|
ORR
Time Frame: at the time of 8 weeks (2 cycles after treatment)
|
Treatment response are defined as complete response (CR), partial response (PR), stable disease (SD) and progression disease (PD) according to Response Evaluation Criteria in Solid Tumor (RECISIT criteria, version 1.1).
The percentage of patients who achieved CR and PR was defined as objective response rate (ORR)
|
at the time of 8 weeks (2 cycles after treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DCR
Time Frame: at the time of 8 weeks (2 cycles after treatment)
|
Treatment response are defined as complete response (CR), partial response (PR), stable disease (SD) and progression disease (PD) according to Response Evaluation Criteria in Solid Tumor (RECISIT criteria, version 1.1) and the percentage of patients who achieved CR, PR and SD was defined as disease control rate (DCR).
|
at the time of 8 weeks (2 cycles after treatment)
|
PFS
Time Frame: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months
|
PFS is defined as the time from the date of treatment to the first date of disease progression or death from any cause.
|
From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months
|
OS
Time Frame: From date of treatment until the date of death from any cause, assessed up to 50 months
|
OS is calculated from diagnosis to death or last follow-up time.
|
From date of treatment until the date of death from any cause, assessed up to 50 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 20, 2018
Primary Completion (Anticipated)
December 31, 2019
Study Completion (Anticipated)
December 31, 2020
Study Registration Dates
First Submitted
August 7, 2018
First Submitted That Met QC Criteria
August 9, 2018
First Posted (Actual)
August 14, 2018
Study Record Updates
Last Update Posted (Actual)
August 14, 2018
Last Update Submitted That Met QC Criteria
August 9, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protein Kinase Inhibitors
- Folic Acid Antagonists
- Gemcitabine
- Carboplatin
- Erlotinib Hydrochloride
- Pemetrexed
Other Study ID Numbers
- ACTION
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
The data used or analyzed during the current study are available from the principle investigator on reasonable request after 6 months of the project is finished.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on Anlotinib,Erlotinib,IBI308,Pemetrexed,gemcitabine,carboplatin
-
The First Affiliated Hospital with Nanjing Medical...UnknownNon-squamous Non-small-cell Lung Cancer
-
Sichuan Cancer Hospital and Research InstituteChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownLung Cancer MetastaticChina
-
Tianjin Medical University Cancer Institute and...Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingResectable Locally Advanced Non-small Cell Lung CancerChina
-
Cancer Institute and Hospital, Chinese Academy...UnknownAdenocarcinoma | NSCLC | Squamous Cell Carcinoma
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedCancer, Solid TumorChina
-
AstraZenecaActive, not recruitingNon Small Cell Lung Cancer NSCLCPoland, United States, Taiwan, Thailand, Vietnam, Korea, Republic of, United Kingdom, Brazil, Hungary, Japan, Mexico, Peru, Russian Federation, China, Germany, South Africa, Ukraine, Bulgaria, Hong Kong
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingAdvanced Non-Small Cell Lung CancerChina
-
The First Affiliated Hospital with Nanjing Medical...RecruitingMetastatic NSCLC | Recurrent NSCLC | Advanced Non-Small Cell Squamous Lung CancerChina
-
AkesoAkeso Tiancheng, IncTerminatedLung Cancer Non-small Cell Stage IVChina
-
Henan Cancer HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownNon-squamous Cell Non-Small Cell Lung CancerChina